PMID- 28944826
OWN - NLM
STAT- MEDLINE
DCOM- 20180606
LR  - 20231124
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 16
IP  - 5
DP  - 2017 Nov
TI  - MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell 
      lung cancer.
PG  - 7329-7336
LID - 10.3892/mmr.2017.7517 [doi]
AB  - Non‑small‑cell lung cancer (NSCLC) accounts for ~80% of human lung cancers that 
      result in mortalities worldwide. Metastasis‑associated in colon cancer‑1 (MACC‑1) 
      has been demonstrated to be significantly expressed in cases of NSCLC and 
      promotes tumor cell migration and metastasis through transactivation of the 
      metastasis‑inducing hepatocyte growth factor/MET proto‑gene, receptor tyrosine 
      kinase (HGF/MET) signaling pathway. The present study constructed a chimeric 
      antibody (Chanti‑MACC‑1) targeting MACC‑1 and investigated its potential as a 
      molecular therapeutic target in the treatment of NSCLC therapy. The expression of 
      MACC‑1 was detected by reverse transcription‑quantitative polymerase chain 
      reaction and western blotting in lung cancer cell lines and tissues. MTT assay 
      was used to detect proliferation of A549 cells treated by Chanti‑MACC‑1, whereas 
      the functional and regulatory effects of Chanti‑MACC‑1 in the migration and 
      metastasis of NSCLC cells was investigated by a cell invasion assay. The 
      therapeutic effect and survival time was observed in animal models. The results 
      demonstrated that MACC‑1 expression was increased and overexpression of MACC‑1 
      promoted the progression of the cell cycle, significantly promoted NSCLC cell 
      growth and enhanced tumor migration and invasion through the HGF/MET signaling 
      pathway. It was further demonstrated that Chanti‑MACC‑1 efficiently suppressed 
      MACC‑1 expression and significantly inhibited NSCLC cell proliferation, migration 
      and invasion by blocking the HGF/MET signaling pathway. The data revealed that 
      Chanti‑MACC‑1 was not only beneficial for tumor remission, however additionally 
      contributed to the long‑term survival of NSCLC ‑bearing mice. The findings of the 
      present study indicated that MACC‑1 was significantly upregulated and promoted 
      tumor cell growth and migration in NSCLC cells and tissues via transactivation of 
      the metastasis‑inducing HGF/MET signaling pathway. However, 
      Chanti‑MACC‑1significantly inhibited tumor growth and metastasis, which suggested 
      that MACC‑1 may be essential for tumor initiation and progression by negatively 
      regulating tumor suppressors.
FAU - Shi, Woda
AU  - Shi W
AD  - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu 215006, P.R. China.
FAU - Song, Jianxiang
AU  - Song J
AD  - Department of Cardiothoracic Surgery, The Third People's Hospital, Yancheng, 
      Jiangsu 224001, P.R. China.
FAU - Wang, Wencai
AU  - Wang W
AD  - Department of Cardiothoracic Surgery, The Third People's Hospital, Yancheng, 
      Jiangsu 224001, P.R. China.
FAU - Zhang, Yajun
AU  - Zhang Y
AD  - Department of Cardiothoracic Surgery, The Third People's Hospital, Yancheng, 
      Jiangsu 224001, P.R. China.
FAU - Zheng, Shiying
AU  - Zheng S
AD  - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu 215006, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20170919
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (MACC1 protein, human)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
RIN - Mol Med Rep. 2024 Jan;29(1):. PMID: 37997799
MH  - A549 Cells
MH  - Animals
MH  - Antibodies, Monoclonal/genetics/metabolism/*pharmacology/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/metabolism/*pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/*drug effects
MH  - Down-Regulation/drug effects
MH  - Epithelial-Mesenchymal Transition/drug effects
MH  - Female
MH  - Hepatocyte Growth Factor/metabolism
MH  - Humans
MH  - Lung Neoplasms/drug therapy/metabolism/*pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Microscopy, Fluorescence
MH  - Proto-Oncogene Proteins c-met/metabolism
MH  - Recombinant Fusion Proteins/biosynthesis/genetics/pharmacology/therapeutic use
MH  - Signal Transduction/drug effects
MH  - Trans-Activators
MH  - Transcription Factors/genetics/*immunology/metabolism
MH  - Transplantation, Heterologous
PMC - PMC5865862
EDAT- 2017/09/26 06:00
MHDA- 2018/06/07 06:00
PMCR- 2017/09/19
CRDT- 2017/09/26 06:00
PHST- 2016/04/04 00:00 [received]
PHST- 2017/08/14 00:00 [accepted]
PHST- 2017/09/26 06:00 [pubmed]
PHST- 2018/06/07 06:00 [medline]
PHST- 2017/09/26 06:00 [entrez]
PHST- 2017/09/19 00:00 [pmc-release]
AID - mmr-16-05-7329 [pii]
AID - 10.3892/mmr.2017.7517 [doi]
PST - ppublish
SO  - Mol Med Rep. 2017 Nov;16(5):7329-7336. doi: 10.3892/mmr.2017.7517. Epub 2017 Sep 
      19.